Edition:
United States

Novartis AG (NVS)

NVS on New York Consolidated

87.52USD
24 May 2019
Change (% chg)

$3.08 (+3.65%)
Prev Close
$84.44
Open
$86.49
Day's High
$88.44
Day's Low
$86.32
Volume
4,727,218
Avg. Vol
2,408,375
52-wk High
$96.31
52-wk Low
$72.30

About

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines... (more)

Overall

Beta: 0.75
Market Cap(Mil.): $224,870.50
Shares Outstanding(Mil.): 2,616.84
Dividend: 2.72
Yield (%): 3.17

Financials

  NVS Industry Sector
P/E (TTM): 31.31 29.30 32.55
EPS (TTM): 2.74 -- --
ROI: 6.14 14.23 13.82
ROE: 9.19 15.46 15.25

Novartis $2 million gene therapy for rare disorder is world's most expensive drug

ZURICH/NEW YORK, Swiss drugmaker Novartis on Friday won U.S. approval for its gene therapy Zolgensma for spinal muscular atrophy (SMA), the leading genetic cause of death in infants, and priced the one-time treatment at a record $2.125 million. | Video

May 24 2019

UPDATE 5-Novartis $2 mln gene therapy for rare disorder is world's most expensive drug

ZURICH/NEW YORK, May 24, Swiss drugmaker Novartis on Friday won U.S. approval for its gene therapy Zolgensma for spinal muscular atrophy (SMA), the leading genetic cause of death in infants, and priced the one-time treatment at a record $2.125 million.

May 24 2019

Novartis' breast cancer treatment wins FDA approval

The U.S. Food and Drug Administration (FDA) said on Friday that it had approved Novartis AG's treatment in combination with a hormone therapy for postmenopausal women, as well as for men, with a form of advanced breast cancer.

May 24 2019

UPDATE 1-Novartis' breast cancer treatment wins FDA approval

May 24 The U.S. Food and Drug Administration (FDA) said on Friday that it had approved Novartis AG's treatment in combination with a hormone therapy for postmenopausal women, as well as for men, with a form of advanced breast cancer.

May 24 2019

Novartis' breast cancer treatment wins FDA approval

May 24 The U.S. Food and Drug Administration (FDA) said on Friday it approved Novartis AG's treatment in combination with hormone therapy fulvestrant for postmenopausal women, as well as men, with a form of advanced breast cancer.

May 24 2019

BRIEF-FDA Approves Novartis' Piqray, the First Pi3k Inhibitor For Breast Cancer

* FDA- ALSO APPROVED COMPANION DIAGNOSTIC TEST, THERASCREEN PIK3CA RGQ PCR KIT, TO DETECT PIK3CA MUTATION IN A TISSUE AND/OR A LIQUID BIOPSY Source text for Eikon: Further company coverage:

May 24 2019

CORRECTED-U.S. approves Novartis gene therapy for rare, deadly muscle disorder

NEW YORK/ZURICH, May 24 - Swiss drugmaker Novartis won U.S. approval for its gene therapy Zolgensma for spinal muscular atrophy (SMA), the leading genetic cause of death in infants, the company said on Friday, a one-time treatment expected to push the pricing boundary for rare diseases to new heights.

May 24 2019

BRIEF-Novartis Says Zolgensma Wholesale Acquisition Cost Will Be $2.125 Million

* SAYS ZOLGENSMA WHOLESALE ACQUISITION COST WILL BE $2.125 MILLION Source text for Eikon: Further company coverage: (Reporting By Michael Erman)

May 24 2019

BRIEF-Avexis Receives FDA Approval For Zolgensma, First And Only Gene Therapy For Pediatric Patients With Spinal Muscular Atrophy

* AVEXIS RECEIVES FDA APPROVAL FOR ZOLGENSMA®, THE FIRST AND ONLY GENE THERAPY FOR PEDIATRIC PATIENTS WITH SPINAL MUSCULAR ATROPHY (SMA)

May 24 2019

Novartis CEO sees chance to accelerate profit margin target

ZURICH Novartis could reach its main drugs business's margin target "a little sooner" than 2022, as it now forecasts, as it cuts costs and as new drugs including gene therapy accelerate, Chief Executive Vas Narasimhan told investors.

May 23 2019

Earnings vs. Estimates